ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

Impact · against what's priced in

ADXN extends its cash runway into Q4 2027 via a $2.8 million ATM offering. This reduces near-term insolvency risk, though it introduces minor dilution through the issuance of 437,869 ADSs.

ADXN+0.40: No priced-in read yet
In context

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

What matters in this story

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Track these names every morning.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

Glaukos: The Second J-Code Rewrites The Risk Math

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027

What matters in this story

Next reads from the same story arc

Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity

How each ticker is affected

Track these names every morning.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage

Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value

Glaukos: The Second J-Code Rewrites The Risk Math